NTRK gene fusions

Home/Tag: NTRK gene fusions

Important Research Study Holds Hope for “Quadruple Wildtype” GIST Patients

A recent study published in the Journal of Translational Medicine, presents important research findings for the 10-15% of GIST patients who lack mutations in KIT, PDGFRA, SDHX or RAS pathway indicators, the primary oncogenic [...]

By |2018-10-30T09:25:15-04:00January 6th, 2017|News, Research|

Loxo Oncology Announces Plans for LOXO-101

In a recent press release, Loxo Oncology announced an update on the status of their TRK (tropomyosin receptor kinase) inhibitor drug, larotrectinib (LOXO-101). Larotrectinib targets the NTRK genes, which encode for the TRK kinases. [...]

By |2020-02-21T15:03:40-05:00December 22nd, 2016|Clinical Trials, News, Research|

Wildtype Track at Life Fest 2016 Provided Informative Sessions

The following are summaries of two of the Wild Type GIST parallel track sessions at Life Fest, 2016, submitted by Rebecca Bensenhaver of GSI International.  "I was fortunate to be able to attend Life [...]

By |2018-10-30T09:34:54-04:00August 19th, 2016|GIST Education, News|

LOXO-101 receives breakthrough therapy designation from FDA for solid tumors with NTRK gene fusions

Loxo Oncology  announced in a press release that the FDA has granted breakthrough therapy designation to LOXO-101 for the treatment of unresectable or metastatic solid tumors with neurotrophic tyrosine receptor kinase gene fusions. This [...]

By |2020-02-21T14:56:38-05:00July 21st, 2016|News, Research|

LOXO-101 Holds Promise as Potential Treatment Targeting Solid Tumors

A recent announcement from the University of Texas MD Anderson Cancer Center described a study that shows promise for a potential treatment (LOXO-101) that targets solid tumors with NTRK gene fusions. The investigational agent, [...]

By |2018-10-30T09:50:34-04:00May 19th, 2016|News, Research|
Go to Top